Back to Journals » ClinicoEconomics and Outcomes Research » Volume 11

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies [Corrigendum]

Authors Ferrufino CP, Munakata J, Wei W, Proudfoot C, Kuznik A, Boklage SH, Chen C

Received 27 December 2018

Accepted for publication 27 December 2018

Published 14 January 2019 Volume 2019:11 Pages 83—85

DOI https://doi.org/10.2147/CEOR.S199650


Ferrufino CP, Munakata J, Wei W, et al. Clinicoecon Outcomes Res. 2018;10: 805—819.
 
On page 810, Table 4, Drug costs column, Methotrexate, the Unit WAC was listed as $1 however it should have been $2.36. On page 817, Table S2, the monitoring costs for (A) csDMARD-IR and (B) TNF-IR were changed.
 
Read the original article

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]